Landscape of granted US patents in personalized diagnostics for oncology from 2014 to 2018 [0.03%]
2014年至2018年美国已授权的肿瘤个性化诊断专利图谱分析
Steven B Ouellette
Steven B Ouellette
Personalized diagnostic testing (PDx) is a key component of the precision medicine toolkit and has shown the most development in cancer applications. Recent changes in the regulatory and legal landscapes regarding PDx development and commer...
ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents [0.03%]
DNA解旋酶和拓扑异构酶IV抑制剂作为抗菌剂的 ATP竞争性化合物
Martina Durcik,Tihomir Tomašič,Nace Zidar et al.
Martina Durcik et al.
Introduction: The bacterial topoisomerases DNA gyrase and topoisomerase IV are validated targets for development of novel antibacterial agents. Fluoroquinolones inhibit the catalytic GyrA and/or ParC(GrlA) subunit and hav...
Systematic review and technological prospection: ethyl ferulate, a phenylpropanoid with antioxidant and neuroprotective actions [0.03%]
系统评价与技术预见：乙基原儿茶酸的抗氧化和神经保护作用
Francisco Valmor Macedo Cunha,Angélica Gomes Coelho,Pedro Simão da Silva Azevedo et al.
Francisco Valmor Macedo Cunha et al.
Introduction: Ethyl ferulate is a phenylpropanoid with anti-inflammatory, antioxidant and neuroprotective activities of natural and synthetic origin with potential uses in the nutraceutical and pharmaceutical industry. Th...
GPR17 receptor modulators and their therapeutic implications: review of recent patents [0.03%]
GPR17受体调节剂及其治疗意义：近期专利综述
Gabriella Marucci,Diego Dal Ben,Catia Lambertucci et al.
Gabriella Marucci et al.
Introduction: The GPR17 receptor, phylogenetically related to both purinergic P2Y and CysLT receptors, is mainly expressed in the CNS and, in general, in organs that can typically undergo ischemic damage. This receptor is...
A patent review of arginine methyltransferase inhibitors (2010-2018) [0.03%]
2010-2018年精氨酸甲基转移酶抑制剂专利综述
Xiao Li,Chen Wang,Hao Jiang et al.
Xiao Li et al.
Introduction: Protein arginine methyltransferases (PRMTs) are fundamental enzymes that specifically modify the arginine residues of versatile substrates in cells. The aberrant expression and abnormal enzymatic activity of...
Research and development of anti-Parkinson's drugs: an analysis from the perspective of technology flows measured by patent citations [0.03%]
帕金森病药物的研发：基于专利引文的技术流视角分析
Jingwen Qu,Jiahong Lu,Yuanjia Hu
Jingwen Qu
Introduction: By 2020, nearly one million people will live with Parkinson's disease (PD) in the U.S. This disorder has a significant impact on patients' quality of life and is a burden on families and society. Protracted ...
Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018) [0.03%]
选择性TYK2抑制剂作为潜在治疗药物：2015-2018年专利回顾
Xingrui He,Xiabin Chen,Hancheng Zhang et al.
Xingrui He et al.
Introduction: Tyrosine kinase 2 (Tyk2) is a non-receptor tyrosine-protein kinase, an enzyme that in humans is encoded by the TYK2 gene. Tyk2, together with three other family subtypes, namely, Jak1, Jak2, and Jak3, belong...
Scientific and technological prospection on transdermal formulations and complementary therapies for the treatment of primary dysmenorrhea [0.03%]
治疗原发性痛经透皮给药剂型和辅助疗法的科技趋势与前瞻预测研究杂文
Sávia Francisca Lopes Dias,Layane Carneiro Alves Pereira,Aldeidia Pereira de Oliveira et al.
Sávia Francisca Lopes Dias et al.
Introduction: Primary dysmenorrhea (PD) is another term for idiopathic menstrual cramps. Treatments include the use of oral non-steroidal anti-inflammatory drugs (NSAIDs). These drugs have several side effects. The object...
The use of terpenes and derivatives as a new perspective for cardiovascular disease treatment: a patent review (2008-2018) [0.03%]
单萜及其衍生物作为心血管疾病治疗新思路的专利分析（2008-2018）
Eric Aian P Silva,Jéssica S Carvalho,Adriana G Guimarães et al.
Eric Aian P Silva et al.
Introduction: Terpenes are a class of secondary metabolites that can be found in a variety of animal and plants species. They are considered the most structurally diversified and abundant of all natural compounds. Several...
Targeted treatment of anaerobic cancer. Patent evaluation of US2016279084 and US2017056350 [0.03%]
厌氧癌症的靶向治疗.US2016279084和US2017056350专利评估
Giuseppina De Simone
Giuseppina De Simone
Based on the initial studies of J. Folkman in 1970s, which led to the proposal of the antiangiogenic therapy, many drugs targeting VEGF or its receptors have been developed with some of them approved for cancer treatment. However, these mol...